Spinosad
As of the edition of 20 October 2026, Spinosad is a small molecule: marketed, first approved in 2011 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Natroba
- First approved
- 18 January 2011 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Cipher Pharmaceuticals
- Registered trials
- 9, 0 stopped early
- Disease areas
- Infections; Skin and connective tissue; Immune system; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| ParaPRO | Originator and Lead sponsor of trials | 2007 to now |
| Cipher Pharmaceuticals | Acquired holder and Lead sponsor of trials | 2022 to now |